Therapy Detail
Contact
Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | MK-7684A |
| Synonyms | |
| Therapy Description |
MK-7684A is a co-formulation of the immune checkpoint inhibitor Keytruda (pembrolizumab) and MK-7684 (Vibostolimab), an antibody directed against T-cell immunoreceptor with Ig and ITIM domains (TIGIT), which may lead to the activation of immune response against tumor cells (NCI Drug Dictionary). |
Filtering
- Case insensitive filtering will display rows if any text in any cell matches the filter term
- Use simple literal full or partial string matches
- Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
- Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
- Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")
Sorting
- Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
- Click on any column header arrows to sort by that column
- Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| MK-7684A | MK-7684/MK-3475|Vibostolimab/Pembrolizumab | Immune Checkpoint Inhibitor 149 PD-L1/PD-1 antibody 122 TIGIT Antibody 19 | MK-7684A is a co-formulation of the immune checkpoint inhibitor Keytruda (pembrolizumab) and MK-7684 (Vibostolimab), an antibody directed against T-cell immunoreceptor with Ig and ITIM domains (TIGIT), which may lead to the activation of immune response against tumor cells (NCI Drug Dictionary). |
Filtering
- Case insensitive filtering will display rows if any text in any cell matches the filter term
- Use simple literal full or partial string matches
- Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
- Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
- Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")
Sorting
- Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
- Click on any column header arrows to sort by that column
- Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| CD274 positive | head and neck squamous cell carcinoma | predicted - sensitive | MK-7684A | Phase II | Actionable | In a Phase II trial (KEYVIBE-005), MK-7684A treatment resulted in an objective response rate (ORR) of 29% (12/42), a median duration of response of 12.7 months, a median progression survival of 4.1 months, and a median overall survival of 15.5 months in patients with CD274 (PD-L1)-positive (CPS>/=1) head and neck squamous cell carcinoma, with an ORR of 21% (5/24) in patients with CPS=1-19 and an ORR of 41% with CPS>/=20 (Ann Oncol (2024) 35 (Suppl_2): S617-S618; NCT05007106). | detail... |
Filtering
- Case insensitive filtering will display rows if any text in any cell matches the filter term
- Use simple literal full or partial string matches
- Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
- Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
- Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")
Sorting
- Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
- Click on any column header arrows to sort by that column
- Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT04738487 | Phase III | Pembrolizumab MK-7684A | Coformulation of Pembrolizumab/Vibostolimab (MK-7684A) Versus Pembrolizumab (MK-3475) Monotherapy for Programmed Cell Death 1 Ligand 1 (PD-L1) Positive Metastatic Non-Small Cell Lung Cancer (MK-7684A-003, KEYVIBE-003) | Active, not recruiting | USA | TUR | ROU | HUN | CAN | BRA | 17 |
| NCT05665595 | Phase III | Pembrolizumab MK-7684A | A Study of Adjuvant Pembrolizumab/Vibostolimab (MK-7684A) Versus Pembrolizumab for Resected High-Risk Melanoma in Participants With High-Risk Stage II-IV Melanoma (MK-7684A-010/KEYVIBE-010) | Active, not recruiting | USA | TUR | SWE | POL | NZL | ITA | ISR | IRL | GBR | FRA | ESP | DEU | CHE | CAN | BRA | BEL | AUT | AUS | ARG | 7 |
| NCT04725188 | Phase II | Docetaxel Docetaxel + MK-7684A MK-7684A | Pembrolizumab/Vibostolimab Coformulation (MK-7684A) or Pembrolizumab/Vibostolimab Coformulation Plus Docetaxel Versus Docetaxel for Metastatic Non Small Cell Lung Cancer (NSCLC) With Progressive Disease After Platinum Doublet Chemotherapy and Immunotherapy (MK-7684A-002, KEYVIBE-002) | Completed | USA | POL | ITA | ISR | FRA | FIN | ESP | DNK | DEU | CHE | BRA | BEL | AUT | AUS | ARG | 5 |
| NCT06395090 | Phase Ib/II | MK-7684A MK-4280 + Pembrolizumab Pembrolizumab + Vibostolimab MK-4280A | A Study of Pembrolizumab in Combination With Investigational Agents in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01B/LIGHTBEAM-U01) | Withdrawn | USA | 2 |
| NCT05007106 | Phase II | MK-7684A + Paclitaxel Cisplatin + Fluorouracil + MK-7684A Pembrolizumab Lenvatinib + MK-7684A MK-7684A | MK-7684A With or Without Other Anticancer Therapies in Participants With Selected Solid Tumors (MK-7684A-005) (KEYVIBE-005) | Active, not recruiting | USA | TUR | POL | NLD | ITA | ISR | FRA | ESP | DEU | CAN | 5 |
| NCT04895722 | Phase II | MK-4280A MK-7684A MK-1308A MK-4830 + Pembrolizumab Pembrolizumab | Evaluation of Co-formulated Pembrolizumab/Quavonlimab (MK-1308A) Versus Other Treatments in Participants With Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Stage IV Colorectal Cancer (CRC) (MK-1308A-008/KEYSTEP-008) | Active, not recruiting | USA | TUR | ROU | POL | NLD | LTU | ITA | HUN | GRC | GBR | FRA | EST | ESP | DNK | DEU | CAN | BEL | 5 |
| NCT05005442 | Phase II | MK-7684A | A Study of Pembrolizumab/Vibostolimab (MK-7684A) in Relapsed/Refractory Hematological Malignancies (MK-7684A-004) | Completed | USA | TUR | POL | ITA | ISR | HUN | FRA | ESP | DNK | DEU | CAN | BRA | 4 |
CKB BOOST